| BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells P Tassone, P Tagliaferri, A Perricelli, S Blotta, B Quaresima, ML Martelli, ... British journal of cancer 88 (8), 1285-1291, 2003 | 456 | 2003 |
| Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma J Rosenblatt, B Vasir, L Uhl, S Blotta, C MacNamara, P Somaiya, Z Wu, ... Blood, The Journal of the American Society of Hematology 117 (2), 393-402, 2011 | 259 | 2011 |
| Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications J Jakubikova, S Adamia, M Kost-Alimova, S Klippel, D Cervi, JF Daley, ... Blood, The Journal of the American Society of Hematology 117 (17), 4409-4419, 2011 | 182 | 2011 |
| Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ... Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012 | 154 | 2012 |
| RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma AK Azab, F Azab, S Blotta, CM Pitsillides, B Thompson, JM Runnels, ... Blood, The Journal of the American Society of Hematology 114 (3), 619-629, 2009 | 140 | 2009 |
| Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo MA Shammas, H Koley, RC Bertheau, P Neri, M Fulciniti, P Tassone, ... Leukemia 22 (7), 1410-1418, 2008 | 127 | 2008 |
| Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma J Jakubikova, D Cervi, M Ooi, K Kim, S Nahar, S Klippel, D Cholujova, ... Haematologica 96 (8), 1170, 2011 | 92 | 2011 |
| Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance S Blotta, P Tassone, RH Prabhala, P Tagliaferri, D Cervi, S Amin, ... Blood, The Journal of the American Society of Hematology 114 (15), 3276-3284, 2009 | 51 | 2009 |
| Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents P Tassone, S Blotta, C Palmieri, S Masciari, B Quaresima, M Montagna, ... International journal of oncology 26 (5), 1257-1263, 2005 | 33 | 2005 |
| Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma P Neri, P Tassone, M Shammas, H Yasui, E Schipani, RB Batchu, S Blotta, ... Leukemia 21 (12), 2519-2526, 2007 | 28 | 2007 |
| Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways P Tagliaferri, P Tassone, S Blotta, C Viscomi, F Grillone, A Budillon, ... Current Drug Targets 6 (3), 289-300, 2005 | 18 | 2005 |
| In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells P Neri, H Yasui, T Hideshima, P Tassone, N Raje, CP Laurence, ... British journal of haematology 134 (1), 37-44, 2006 | 17 | 2006 |
| Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma. M Fulciniti, P Tassone, T Hideshima, S Vallet, S Ettenberg, D Stover, ... Blood, The Journal of the American Society of Hematology 110 (11), 551-551, 2007 | 8 | 2007 |
| A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models. G Gorgun, E Calabrese, M Mani, T Hideshima, H Ikeda, G Perrone, ... Blood 112 (11), 1719, 2008 | 5 | 2008 |
| Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias AM Roccaro, IM Ghobrial, S Blotta, SP Treon, M Malagola, KC Anderson, ... Biologics: Targets and Therapy 2 (3), 419-431, 2008 | 3 | 2008 |
| Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial G Martinelli, A Santoro, C Gambacorti-Passerini, SV Polo, SR Solomon, ... J. Clin. Oncol 40 (7024), 10.1200, 2022 | 2 | 2022 |
| Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical … J Jakubikova, DN Cervi, JF Daley, D Cholujova, MG Ooi, S Klippel, ... Blood 114 (22), 954, 2009 | 2 | 2009 |
| TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma. R Prabhala, D Pelluru, P Neri, M Fulciniti, JJ Driscoll, S Weihua, S Blotta, ... Blood, The Journal of the American Society of Hematology 110 (11), 3517-3517, 2007 | 2 | 2007 |
| The novel, orally available multi-kinase inhibitor BAY 73-4506 in multiple myeloma I Breitkreutz, MS Raab, O Christensen, A Zimmerhackl, J Zhang, S Blotta, ... Blood, The Journal of the American Society of Hematology 112 (11), 2766-2766, 2008 | 1 | 2008 |
| Waldenström macroglobulinemia: new therapeutic options AM Roccaro, X Leleu, S Blotta, N Burwik, A Vacca, D Russo, IM Ghobrial Cancer Therapy 6, 227-238, 2008 | 1 | 2008 |
